妇女健康倡议中他汀类药物使用与子宫内膜癌和卵巢癌风险关联的分析
基于妇女健康倡议(WHI)161,808名绝经后女性平均10.8年随访数据,基线他汀使用与子宫内膜癌风险降低相关(HR 0.74,95%CI 0.59-0.94),但与卵巢癌风险无显著关联;时间依赖模型中他汀使用与子宫内膜癌无显著关联,却与卵巢癌风险升高相关(HR 1.30,95%CI 1.04-1.62),主要归因于普伐他汀(HR 1.89,95%CI 1.24-2.88)。
要点
- 基线他汀使用与子宫内膜癌风险降低相关(HR 0.74,95%CI 0.59-0.94)。
- 时间依赖模型中他汀使用与子宫内膜癌风险无显著关联(HR 0.91,95%CI 0.76-1.08)。
- 时间依赖模型中他汀使用与卵巢癌风险升高相关(HR 1.30,95%CI 1.04-1.62),主要归因于普伐他汀(HR 1.89,95%CI 1.24-2.88)。
核心结论
- 基线他汀使用者子宫内膜癌风险降低,但时间依赖模型中未见此关联;普伐他汀使用与卵巢癌风险升高相关;需要更大样本的病例分析来评估这些发现。
研究设计与样本
- 妇女健康倡议(WHI)队列研究,纳入161,808名绝经后女性,平均随访10.8年(标准差3.3年),期间新发子宫内膜癌1377例、卵巢癌763例。
主要发现
- 基线他汀使用率为7.5%,至第9年使用率高达25%。
- 基线他汀使用与子宫内膜癌风险的多变量校正HR为0.74(95%CI 0.59-0.94),与卵巢癌风险的HR为1.15(95%CI 0.89-1.50)。
- 时间依赖模型中,他汀使用与子宫内膜癌风险无显著关联(HR 0.91,95%CI 0.76-1.08),但与卵巢癌风险升高相关(HR 1.30,95%CI 1.04-1.62),主要归因于亲水性他汀普伐他汀(HR 1.89,95%CI 1.24-2.88)。
局限性
- 需要更大样本的病例分析来评估这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statins have anti proliferative activity in vitro against endometrial and ovarian cancer and can affect levels of reproductive hormones. We analyzed data from the Women's Health Initiative (WHI) to assess whether statins are associated with risk of endometrial and ovarian cancer. METHODS: The WHI study included 161,808 postmenopausal women in which incident cases of endometrial (n = 1377) and ovarian cancer (n = 763) were identified over an average of 10.8 (SD + 3.3) years. Information on statin use and risk factors was collected at baseline and follow-up. Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for the association of statin use and risk of endometrial and ovarian cancer. All statistical tests were two-sided. RESULTS: Statins were used at baseline by 7.5% women and by up to 25% at year nine. The multivariable adjusted HR for risk of endometrial cancer for baseline statin use was 0.74, 95% C.I. 0.59-0.94 and for ovarian cancer was 1.15, 95% C.I. 0.89-1.50. In time-dependent models, statins were not associated with endometrial cancer (HR 0.91, 95% C.I. 0.76-1.08) however there was an increased risk of ovarian cancer (HR 1.30, 95% CI 1.04-1.62), largely attributed to the effect of the hydrophilic statin, pravastatin (1.89, 95% CI 1.24-2.88). CONCLUSIONS: There was a reduction in risk of endometrial cancer among statin users at baseline but not in time-dependent models. Pravastatin use was associated with an increased risk of ovarian cancer. Analyses of larger numbers of cases are needed to evaluate these findings.
引用
- Desai P, Wallace R, Anderson ML, et al. An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative. Gynecol Oncol. 2018. PMID: 29422345. doi:10.1016/j.ygyno.2018.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。